In December 2016, Mercachem and Almirall announced that Almirall had obtained exclusive rights to Mercachem’s cytokine blockers, and a research collaboration was initiated to optimize these molecules towards candidates for clinical development.
Today, Mercachem is proud to announce the achievement of the first milestone of this research collaboration.
“We are delighted to announce that we have achieved the first milestone within 15 months of collaboration,” said Eelco Ebbers, co-founder and Managing Director of Mercachem. “This shows the innovative research capabilities of Mercachem to progress challenging targets and chemistries, and also demonstrates the true strength of working in partnerships.”
Contact us
News Archive
-
2018
-
2017
- Microwave-Assisted Synthesis of Drug-Like Libraries
- Finalist of the Gouden Spatel Prize 2016: Yoeri Janssen
- Mercachem–Syncom Group Announces the Appointment of Dr. Luc Van Hijfte as Senior Vice President of Medicinal Chemistry
- Mercachem and Syncom Join Forces to Form Europe’s Premier Drug Discovery CRO
- New Autotaxin Inhibitors Published by Mercachem and Galapagos
- Mercachem Patents Synthesis of IP-free Scaffolds Derived from Natural Products
- InHolland Students Show: The Future of Drug Discovery Looks Bright!
- Publication: Improved 2-oxa-6-azaspiro[3.3]heptane Synthesis
- Novel κ Agonists Reported in Journal of Medicinal Chemistry
- 30,000 Compounds for the ELF Project!
- Mercachem and Syngenta: A 15 Year Discovery Collaboration in Patents!
- Marcel Scheepstra Wins KNCV Dutch Medicinal Chemistry Prize 2015–2016
- AiCuris selects Mercachem as Preferred Medicinal Chemistry Partner
- New CIR Accreditation Granted!
- Mercachem and UbiQ Join Forces to Tackle SUMOylation
- Patent: Lisdexamfetamine Production Improved by Enzymatic Catalysis